Introduction {#Sec1}
============

The World Health Organization on March 11th 2020 declared the novel coronavirus infection COVID-19 a global pandemic \[[@CR1], [@CR2]\]. Italy, particularly the area of Cremona located in the northern region, was notified as the first European country where severe acute respiratory syndrome due to COVID-19 (SARS-CoV-2) was spreading \[[@CR2]\].

From February 21st until the end of March, 1328 patients were admitted to the Hospital of Cremona with confirmed diagnosis of COVID-19 pneumonia.

As known, patients hospitalized for acute medical illnesses, such as pneumonia, congestive respiratory failure, acute infection, rheumatic disorders, acute arthritis, or inflammatory bowel disease, show an increased risk for venous thromboembolism (VTE). Moreover, prolonged immobilization, the association of other acquired or individual risk factor, such as age \> 75 years, cancer, previous venous thromboembolism, obesity or sepsis, further increase thromboembolic risks \[[@CR3]--[@CR9]\].

VTE represents a frequent and potentially fatal complication in hospitalized patients. Pharmacological thromboprophylaxis has shown to significantly reduce VTE events, both in surgical and medical patients, with a relatively low risk of adverse events \[[@CR9]--[@CR12]\].

Evidence-based guidelines recommend use of low-dose parenteral anticoagulants in medically ill patients at high risk for thromboembolism for 6--14 days; while, an extended thromboprophylaxis could be advantageous in patients with additional and persistent risk factors \[[@CR8], [@CR9], [@CR14]\]. Standardized thromboprophylaxis in acute medical ill patients include low dose of parenteral drugs such as unfractionated heparin (UH), low-molecular weight heparin (LMWH), or fondaparinux \[[@CR8]--[@CR13]\].

The incidence of VTE in medically ill patients treated with validated dosages of LMWH is nearly 4.4% \[[@CR10]\] but optimization of thromboprophylaxis has been underlined in special settings such as in sepsis and in obese patients \[[@CR15]--[@CR18]\].

Currently, LMWH enoxaparin 40 mg daily represents the standard of care for venous thromboembolism prevention in acute ill patients in our hospital.

Aim of our study was to evaluate the prevalence of deep vein thrombosis of the legs in a cohort of patients admitted to Internal Medicine of Cremona Hospital, with severe SARS-Cov-2 infection and treated with standard thromboprophylaxis, in a period between 5 and 10 days from hospitalization.

Methods {#Sec2}
=======

Hospital setting {#Sec3}
----------------

The study was conducted in the Internal Medicine Department of Cremona Hospital, in Italy. Starting from February 21, 2020, the 550-bed hospital was transformed to admit patients with COVID-19 pneumonia. Patients were hospitalized in four different COVID dedicated areas: Departments of Infectious Disease, Internal Medicine, Pneumology, and Intensive Care Unit. Patients not needing mechanical ventilation were indistinctly admitted to Infectious Disease, Internal Medicine or Pneumology Departments, altogether including four hundred beds.

Study design {#Sec4}
------------

This single-center cross-sectional study was approved by the Local Ethics Committee. Cross-sectional studies are characterized by the collection of relevant data at a given time-point and this study design is the most relevant design when assessing the prevalence of a disease. Flow chart of the study is detailed in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart of patients' recruitment. Legend: PTS: patients; CVC: central venous catheter; DVT: deep venous thrombosis; CTPA: computed tomographic pulmonary angiogram; CUS: compressive ultrasound; SVT: superficial vein thrombosis

Patients {#Sec5}
--------

On admission at the emergency department, all patients underwent high-resolution computed tomography (HRCT) of the lung or chest X-ray to diagnose pneumonia and a standard LMWH prophylaxis (enoxaparin 40 mg daily) was immediately started.

In a single day (May 31, 2020), all patients who had been hospitalized in Internal medicine department for at least 5 days underwent 2-point compressive ultrasonography of the legs regardless of the presence of DVT symptoms.

Patients' data {#Sec6}
--------------

The following data were recorded in a structured data-base:Demographic, weight, main clinical characteristics such as presence of chronic coexisting diseases, prior VTE, active cancer, in-hospital length of stay (LOS)Pharmacological thromboprophylaxisRespiratory failure and severity of pneumonia: respiratory failure was diagnosed when arterial blood gas analysis showed arterial partial pressure of oxygen (PaO2) less than 60 mmHg.

Pneumonia was categorized according to PaO~2~ and fraction of inspired oxygen (FiO~2~) ratio on admission. Three mutually exclusive categories based on degree of hypoxemia were defined: mild (200--300 mm Hg); moderate (100--199 mm Hg); severe (\< 100 mm Hg). The attending physician established the need of oxygen and/or C-pap support, case by case. Reduced mobilization was considered as bedrest with bathroom privileges (either due to patient's limitations or on physician's order) for at least 3 days \[[@CR19], [@CR20]\].

COVID-19 diagnosis {#Sec7}
------------------

Oropharyngeal swabs were obtained on hospital admission. SARS-CoV-2 RNA was searched using commercial RT-PCR methods (ELITechGroup, Paris, France). GeneFinder™ COVID-19 PlusRealAmp Kit detects Sars-CoV-2 by amplification of RdRp gene, E gene and N gene according to the WHO recommended protocol \[[@CR21]\].

D-dimer assay {#Sec8}
-------------

Plasma samples were collected within the first 24 h from hospitalization in vacuum plastic tubes (Vacutainer, Becton--Dickinson, Plymouth, UK), containing 3.2% trisodium citrate (9:1vol/vol, blood/anticoagulant), centrifuged within 1 h from collection at 2000 g for 15 min and immediately tested.

D-dimer was assessed using a quantitative method (STA Liatest D-dimer) on STA-R, a fully automated multiparameter coagulometer (Stago, France).

A cut-off below 0.5 µg/ml, as recommended by manufacturer for VTE exclusion, was considered as normal plasma level.

Diagnosis of DVT {#Sec9}
----------------

Diagnosis of DVT was performed by a two-region ultrasound protocol according to the recommendations from the Society of Radiologists Ultrasound for lower extremity deep venous thrombosis \[[@CR22]\]. All eligible patients underwent bedside bilateral proximal lower limb compressive ultra-sound (CUS) performed by physicians with trained experience in vascular ultrasound, using the Mindray DC-70 ultrasound machine with a 7.5-MHz linear probe (Fig. [2](#Fig2){ref-type="fig"}). The common femoral vein and the proximal tract of femoral vein were examined first, with the patients lying supine. The popliteal vein to its trifurcation was evaluated with the patients in a (left or right) lateral decubitus or less frequently in the prone position. All compressions were done using B-mode imaging with transverse views by applying compression along the deep venous system of each patient. The diagnostic criterion for DVT was the inability to fully compress the lumen of the vein in the transverse plane \[[@CR23]\].Fig. 2Point of care US in COVID areas

Diagnosis of pulmonary embolism {#Sec10}
-------------------------------

Patients with finding of DVT underwent computed tomography pulmonary angiography (CTPA) examination performed using 64 MD GE Revolution Evo equipment, after administration of 60--80 ml of non-ionic, high-concentration contrast media (370mg/ml) followed by 40 ml saline chaser at at 4--6 ml/s. Angiographic images were acquired in the supine position and cranio-caudal direction with collimation of 0.6 mm, reconstructed with standard algorithm, and slices thickness and interval of 1.25 mm. CT scans were reviewed by expert radiologist in thoracic imaging.

Thromboprophylaxis {#Sec11}
------------------

As per the internal protocol, all the admitted patients with COVID-19-associated pneumonia, received thromboprophylaxis with once-daily subcutaneous administration of a standard dose of enoxaparin 40 mg daily.

Statistical analysis {#Sec12}
--------------------

Descriptive analysis was performed. Continuous variables are expressed as mean and standard deviation, or median ± standard deviation (SD) and range. Categorical variables are expressed as frequencies and percentages.

Results {#Sec13}
=======

On March 31st 2020, 70 out of 121 patients with COVID-19-associated pneumonia were hospitalized for at least 5 days in the Department of Internal Medicine of the Hospital of Cremona; of them, 66 were included in the analysis, while four patients were not tested due to their absence in the ward at the moment of the test for different procedures.

Overall population {#Sec14}
------------------

We scanned 66 patients asymptomatic for DVT from admission to the time point. The mean age was 71.5 years (± 11); patients were mostly males (69.6%). The mean timing of respiratory symptoms onset was 5.1(± 4.1) days before hospital admission. Reduced mobilization affected the 59% of patients. The mean body weight was 77 kg (± 16). Sixty-one % of the patients had respiratory failure (severe 24%; moderate 37%; mild 6%). No patient had clinical and laboratory pattern of disseminated intravascular coagulation (mean values of PT was 1.1 ± 0.1; aPTT 1.0 ± 1.45; fibrinogen 499 ± 176 mg/dl). The mean value of Creatinine clearance was 72.6 ± 31.8 ml/min, and no patient had values less than 30 ml/min. The mean length of hospital stay (LOS) was 12.6 days (± 5). Ninety-four percent of the study population received thromboprophylaxis at admission: 53 patients, enoxaparin 40 mg daily. Nine patients received enoxaparin 60 mg daily because of a perceived higher risk of thrombosis by the attending physician. Five patients were not treated with LMWH because of thrombocytopenia and recent history of bleedings (Table [1](#Tab1){ref-type="table"}). None of the scanned patients had symptoms of DVT.Table 1Main demographic and clinical characteristics of the study populationFeaturesAdmitted patients (*n* = 121)Scanned patients (*n* = 66)Age (mean ± SD) years71.8 ± 1271.5 ± 11Male sex (%)77 (66.3%)46 (69.6%)Body weight (mean ± SD) kg77.1(± 17)77(± 16)Mobilization Yes58 (48%)27(41%) No53 (44%)39 (59%) Unknown10 (8%)0Lenght of hospital stay (Mean days ± SD)8.3 (± 6.5)12.6 (± 5)Clinical history Hypertension38 (31%)22 (33%) Other disease18 (15%)6 (9%) Diabetes17 (14%)9 (13%) Asthma/COPD16 (13%)8 (12%) CAD12 (10%)7 (10%) Cancer11 (9%)6 (9%) CKD11 (9%)4 (6%) Other cardiac diseases11 (9%)8 (12%) Atrial fibrillation8 (6%)3 (4%) Obesity8 (6%)3 (4%) TIA/stroke7 (7%)5 (7%) Previous VTE4 (3%)1 (1%) Haemorrhages2 (2%)0Clinical characteristics Confirmed COVID-19 pneumonia121 (100%)66 (100%) Respiratory failure PaO~2~\< 60 mmHg74 (61%)45 (68%) P/F \< 10025 (20%)16 (24%) P/F 100--20037 (30%)25 (37%) P/F 200--30012 (10%)4 (6%)D-Dimer (µg/ml) D-dimer (mean ± SD)3.25 (± 5.2)3.29 (± 4.6) D-dimer in DVT patients (mean ± SD)4.02 (± 3.55)Enoxaparin daily dose 40 mg10753 60 mg99 No prophyalxis54PaO~2~: arterial partial pressure of oxygen, FiO2: fraction of inspired oxygen, P/F ratio: PaO2/FiO2, DVT: deep vein thrombosis

Among 66 patients, a proximal DVT was confirmed in 9 patients (13.6%), and ruled out in 57 patients; of them, 2 patients without varices had superficial venous thrombosis (SVT). In patients with finding of DVT, a CTPA was performed. Seven patients of nine were scanned; two patients did not undergo the test because of their critical condition. Pulmonary embolism (PE) was confirmed in five cases, as shown in Fig. [1](#Fig1){ref-type="fig"}.

DVT population {#Sec15}
--------------

Nine patients had proximal asymptomatic DVT. The mean age was 75.7 (± 12) years, LOS was 13.8 (± 6) days, they were all males, and the mean body weight was 78 (± 14). Eight out of nine patients had mobility limitations. Only one of them had mild pneumonia, while 8 out of 9 had moderate to severe respiratory failure (4 moderate; 4 severe; 5/9 needed c-pap support). All patients had asymptomatic proximal DVT, bilateral in 3 cases. One patient had a prior DVT. One DVT was catheter associated. CTPA was assessed in seven patients and PE was confirmed in five of them (7.5% of the analyzed patients).

The main demographic and clinical characteristics of the patients with DVT are shown in Table [2](#Tab2){ref-type="table"}Table 2Main demographic and clinical characteristics of patients with asymptomatic proximal DVTPatientGenderAge (years)LOS (days)Enoxaparin (mg/day)MobilizationC-papBody weight (kg)CvCPrevious VTEPneumonia severity^§^D-Dimer (ng/ml)CTPACUS1M62940NoNo50NoYes11.03Not doneLeft popliteal DVT2M56640YesNo77NoNo27.45PEBilateral popliteal DVT3M8160NoYes80NoNo31.41PELeft femoral DVT4M892040NoNo90NoNo22.59NegativeRight popliteal DVT5M802040NoYes98NoNo32.25PEBilateral popliteal DVT6M93940NoYes70IJVNo29.4PEBilateral popliteal DVT7M731940NoYes85NoNo23.0negativeRight popliteal DVT8M712060NoNo70IJVNo3Not donePELeft popliteal DVT9M771640NoYes90CFVNo310.13Not doneCVC-related femoral DVTMean (± SD)75.7 (± 12)13.8 (± 6)78 (± 14)4.02 (± 3.55)Pneumonia severity: 1 = mild; 2 = moderate; 3 = severe; *DVT* deep vein thrombosis, *PE* pulmonary embolism, *LOS* length of hospital stay, *CVC* central venous catheter, *CFV* common femoral vein, *IJV* internal jugular vein, *CTPA* computed tomography pulmonary angiogram, *CUS* compressive ultrasound, *SD* standard deviation, *VTE* venous thromboembolism

Discussion {#Sec16}
==========

Our study shows that in patients admitted to a hospital medical ward because of COVID-19-associated pneumonia, the prevalence of silent proximal DVT was as high as 13.6%, despite standard anticoagulant prophylaxis. This finding could partially explain the high incidence of pulmonary embolism described in previous study and autoptic series \[[@CR24], [@CR25]\]. Furthermore, DVT was frequently bilateral and it was found only in male patients; similarly, a higher prevalence in male subjects has been reported even in a previous study in non-ICU patients \[[@CR26]\]. The novel coronavirus COVID-19 is causing hospitalization of thousands of patients with pneumonia admitted for severe respiratory syndrome \[[@CR1], [@CR2], [@CR27], [@CR28]\]. At hospitalization, patients are managed in relation to severity of respiratory distress and general clinical conditions and admitted to ICU or clinical wards.

Acute medical illness, such as congestive heart failure or respiratory failure, from long time are recognized as clinical conditions at high risk for venous thromboembolism \[[@CR8], [@CR9]\] and standardized parenteral low-dose anticoagulant drugs are recommended and enoxaparin 40 mg daily represents the most commonly adopted regimen in our country.

Patients admitted to Cremona Hospital with COVID-19 are usually treated, in the absence of contraindications such as severe thrombocytopenia, renal impairment, or active bleeding, with standard dose of enoxaparin 40 mg daily for VTE prevention, independent of age and weight.

Our observational study aimed to evaluate the prevalence of asymptomatic DVT in COVID-19 hospitalized patients, treated with the standard regimen of prophylactic LMWH.

Patients were frequently bedridden (59%) with respiratory failure (68%) and, in this specific clinical condition in which respiratory distress is the main persistent symptom associated with decreased PaO~2~, other causes of possible impairment, other than COVID-19 pneumonia, could have been easily overlooked. Furthermore, patients may have also a reduced reactivity to promptly refer symptoms suggestive for DVT that, in any case, should be always confirmed through radiological exams due to poor specificity of clinical signs \[[@CR29]\].

This high prevalence of asymptomatic DVT patients, even with a standard thromboprophylaxis, poses us a crucial question: how and when to suspect VTE in this particular medical condition? Previous studies showed the high mortality rate in patients hospitalized with acute medical illness with asymptomatic proximal DVT \[[@CR30], [@CR31]\].

Since prevalence of VTE in this study population treated with standard dose of LMWH is as high as that observed in the absence of prophylaxis in medical patients \[[@CR10]\], we can suppose that it should be even higher without a pharmacological prevention.

Peculiar characteristics of this viral infection can cause prolonged immobilization, possible dehydration, a massive inflammatory response of the organism that in more severe cases may evolve towards acute respiratory distress syndrome (ARDS), severe coagulopathy and multi-organ failure, all conditions that increase thromboembolic complications. This condition can be associated with increased risks with the need of higher doses of heparin thromboprophylaxis as previously suggested \[[@CR10], [@CR18], [@CR32]--[@CR37]\]; furthermore, acquired antithrombin deficiencies may also occur in these clinical situations, thus causing heparin resistance \[[@CR38], [@CR39]\].

The role of D-Dimer in relation to VTE diagnosis in this study population deserves a special consideration. As shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, high D-Dimer levels have been measured in all patients, despite the result of CUS. Therefore, in this setting, on one hand D-Dimer showed a poor usefulness in relation to its high negative predictive value; whereas, on the other, its correlation between elevated D-Dimer levels and VTE should be better investigated and specific cut-off defined \[[@CR35], [@CR40]--[@CR45]\].

Waiting for further data regarding the proper use of D-Dimer in this clinical condition and based on currently evidences, we consider that early surveillance could be reasonable to promptly avoid DVT complications.

As stated before, the importance of this first study, conducted in hospitalized COVID-19 patients is the evidence of a high prevalence of asymptomatic DVT, despite a standard anticoagulant prophylaxis. On this basis, in our opinion, three important elements should be kept into consideration to properly define the global VTE risk of each single patient in addition to acute infectious disease: (a) Individual risk factors, such as age, weight, sex, cancer, history of previous VTE, that independently increase thromboembolic risk; (b) time of disease onset and time of bed rest and immobilization, to promptly start LMWH prophylaxis; (c) posology of heparin, that should be increased to reach the correct prophylaxis range which may not be "a fixed dose for all", as already proposed in patients with sepsis \[[@CR18], [@CR32]--[@CR34]\].

For the above considerations and highlighting the very high thromboembolic risks of hospitalized COVID-19 patients on standard prophylaxis, we conclude that: (a) routinely compressive ultrasound of the legs should be performed during the first week of hospitalization; (b) LMWH prophylaxis should be started immediately at the onset of acute COVID-19 pneumonia; (c) LMWH prophylaxis should be ensured to all patients, adapting doses in relation to weight, renal function with the target to maintaining upper levels of prophylactic range (aXa = 0.2--0.5 UI/ml) \[[@CR35], [@CR36]\].

Study limitation {#Sec17}
----------------

This study presents several limitations due to its monocenter design and the relatively small sample size; however, it represents the first evidence of the high prevalence of asymptomatic DVT in patients hospitalized with COVID-19 pneumonia, outside intensive care units and despite standard prophylactic dose of LMWH.

Probably, our data underestimated occurrence of DVT, first because we studied only patients with LOS more than 5 days without knowing the right time of the onset of the disease and the mobility limitation before hospitalization.

Second, in our protocol, we use a point of care ultrasound, widely used also in the medical wards \[[@CR46]\] consisting of a two-point CUS evaluation that may underestimates the presence of isolated femoral DVT and does not look at all for calf DVT \[[@CR47], [@CR48]\].

Finally, based on the high frequency of both DVT and PE despite standard anticoagulant prophylaxis, an important knowledge gap remains regarding the optimal time for CUS examination during and after hospital discharge, as well as the optimal LMWH prophylactic treatment and its duration.

Conclusions {#Sec18}
===========

Our observation highlights the high prevalence of asymptomatic proximal DVT in patients hospitalized with COVID-19 pneumonia and the need to implement appropriate active patient surveillance strategies using ultrasound, as well as the adoption of adequate pharmacological thromboprophylaxis.

These findings may have prognostic implications, but larger dedicated studies are warranted.
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